BOSTON SCIENTIFIC CORP (BSX) Stock Price, Forecast & Analysis

NYSE:BSX • US1011371077

74.73 USD
+0.61 (+0.82%)
At close: Feb 13, 2026
74.7246 USD
-0.01 (-0.01%)
After Hours: 2/13/2026, 8:04:00 PM

BSX Key Statistics, Chart & Performance

Key Statistics
Market Cap110.83B
Revenue(TTM)20.07B
Net Income(TTM)2.79B
Shares1.48B
Float1.48B
52 Week High109.5
52 Week Low72.69
Yearly Dividend0
Dividend Yield0%
EPS(TTM)3.05
PE24.5
Fwd PE21.34
Earnings (Next)04-21
IPO1992-05-19
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
BSX short term performance overview.The bars show the price performance of BSX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

BSX long term performance overview.The bars show the price performance of BSX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of BSX is 74.73 USD. In the past month the price decreased by -16.99%. In the past year, price decreased by -29.57%.

BOSTON SCIENTIFIC CORP / BSX Daily stock chart

BSX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
BSX Full Technical Analysis Report

BSX Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to BSX. BSX scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BSX Full Fundamental Analysis Report

BSX Financial Highlights

Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 3.05. The EPS increased by 21.51% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.42%
ROA 6.54%
ROE 11.93%
Debt/Equity 0.48
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%15.9%
EPS 1Y (TTM)21.51%
Revenue 1Y (TTM)19.88%
BSX financials

BSX Forecast & Estimates

40 analysts have analysed BSX and the average price target is 125.5 USD. This implies a price increase of 67.94% is expected in the next year compared to the current price of 74.73.

For the next year, analysts expect an EPS growth of 14.83% and a revenue growth 11.42% for BSX


Analysts
Analysts86
Price Target125.5 (67.94%)
EPS Next Y14.83%
Revenue Next Year11.42%
BSX Analyst EstimatesBSX Analyst Ratings

BSX Ownership

Ownership
Inst Owners94.07%
Ins Owners0.15%
Short Float %1.59%
Short Ratio2.17
BSX Ownership

BSX Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.62193.832B
ISRG INTUITIVE SURGICAL INC47.53169.664B
SYK STRYKER CORP24.21139.908B
BDX BECTON DICKINSON AND CO11.1650.66B
IDXX IDEXX LABORATORIES INC42.4849.283B
EW EDWARDS LIFESCIENCES CORP25.5244.358B
RMD RESMED INC20.5735.869B
GEHC GE HEALTHCARE TECHNOLOGY1635.845B
DXCM DEXCOM INC27.7325.383B

About BSX

Company Profile

BSX logo image Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Company Info

BOSTON SCIENTIFIC CORP

300 Boston Scientific Way

Marlborough MASSACHUSETTS 01752 US

CEO: Michael F. Mahoney

Employees: 53000

BSX Company Website

BSX Investor Relations

Phone: 13026365400

BOSTON SCIENTIFIC CORP / BSX FAQ

What does BOSTON SCIENTIFIC CORP do?

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.


What is the current price of BSX stock?

The current stock price of BSX is 74.73 USD. The price increased by 0.82% in the last trading session.


Does BOSTON SCIENTIFIC CORP pay dividends?

BSX does not pay a dividend.


What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?

BSX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is the employee count for BSX stock?

BOSTON SCIENTIFIC CORP (BSX) currently has 53000 employees.


What is the Short Interest ratio of BOSTON SCIENTIFIC CORP (BSX) stock?

The outstanding short interest for BOSTON SCIENTIFIC CORP (BSX) is 1.59% of its float.